{"analyses":[{"ciLowerLimit":"1.04","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.49","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0172","paramType":"Odds Ratio (OR)","paramValue":"1.25","statisticalMethod":"Proportional Odds Model"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.3","upperLimit":"23.1","value":"20.2"},{"groupId":"OG001","lowerLimit":"22.1","upperLimit":"28.4","value":"25.2"}]}],"title":"Day 7 NIAID-OS 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.8","upperLimit":"8.4","value":"6.6"},{"groupId":"OG001","lowerLimit":"4.1","upperLimit":"7.5","value":"5.8"}]}],"title":"Day 7 NIAID-OS 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"1.1","value":"0.5"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.5","value":"0.2"}]}],"title":"Day 7 NIAID-OS 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.2","upperLimit":"24.1","value":"21.2"},{"groupId":"OG001","lowerLimit":"17.6","upperLimit":"23.5","value":"20.6"}]}],"title":"Day 7 NIAID-OS 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.5","upperLimit":"25.5","value":"22.5"},{"groupId":"OG001","lowerLimit":"19.4","upperLimit":"25.5","value":"22.5"}]}],"title":"Day 7 NIAID-OS 5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.0","upperLimit":"17.0","value":"14.5"},{"groupId":"OG001","lowerLimit":"11.3","upperLimit":"16.2","value":"13.8"}]}],"title":"Day 7 NIAID-OS 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.0","upperLimit":"13.5","value":"11.2"},{"groupId":"OG001","lowerLimit":"8.6","upperLimit":"13.0","value":"10.8"}]}],"title":"Day 7 NIAID-OS 7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"4.5","value":"3.3"},{"groupId":"OG001","lowerLimit":"0.4","upperLimit":"2.0","value":"1.2"}]}],"title":"Day 7 NIAID-OS 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"756"},{"groupId":"OG001","value":"762"}],"units":"Participants"}],"description":"Overall improvement on the National Institute of Allergy and Infectious Diseases ordinal scale:\n\n1\\. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care: (This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6.Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Placebo administered orally QD with standard of care.","id":"OG000","title":"Placebo + SOC"},{"description":"4 mg baricitinib administered orally QD with standard of care.","id":"OG001","title":"Baricitinib + SOC"}],"paramType":"NUMBER","populationDescription":"All participants randomly assigned to study intervention. Participants with missing baseline ordinal scale were excluded.","reportingStatus":"POSTED","timeFrame":"Day 7","title":"Percentage of Participants at Each Clinical Status Using the National Institute of Allergy and Infectious Diseases Ordinal Scale (NIAID-OS) at Day 7","type":"SECONDARY","unitOfMeasure":"percentage of participants"}